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A high IL6/IL17 ratio combined with low IL5
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Cervical cancer is the second leading cause of cancer death
in young women worldwide. The aim of the current study
was to identify which combination of immunological and
vascular factors in the tumor microenvironment of cervi-
cal carcinoma is most significant for survival. Using qRT-
PCR, 42 markers were investigated in frozen squamous
cervical cancer samples (n = 52). Weighted gene co-
expression network analysis and mixed-model analyses
were performed to identify gene expression clusters and
study their correlations. Selected individual factors were
further investigated by immunohistochemistry. We identi-
fied a ‘T cells’ (CD3E/CD8A/TBX21/IFNG/FOXP3/
IDO1), ‘Macrophages’ (CD4/CD14/CD163), ‘Th2’ (IL4/
IL5/IL13/IL12), ‘Inflammation’ (IL6/IL1B/IL8/IL23/IL10/
ARG1), ‘Angiogenesis’ (VEGFA/FLT1/ANGPT2/ PGF/
ICAM1) and ‘Vessel maturation’ (PECAM1/VCAM1/
ANGPT1/SELE/KDR/LGALS9) cluster. The ‘T cells’ clus-
ter significantly correlated with early TNM stage
(p = 0.007). High expression of ‘T cells’ marker CD3E cor-
related with improved disease-specific survival (p = 0.022).
High expression of ‘Angiogenesis’ marker VEGFA corre-
lated with poor survival (p = 0.032). High expression of
‘Inflammation’ marker IL6 was an independent predictor of
poor survival (hazard ratio = 2.3, p = 0.011). A high IL6/
IL17 ratio combined with low IL5 expression gave a hazard
ratio of 4.2 (p = 0.010). Using immunohistochemistry, we
have shown that IL-6 is correlated with poor survival, and
determined that IL-17 was predominantly expressed by
neutrophils (66%), mast cells (23%) and innate lymphoid
cells (8%). Remarkably, Th17 cells were only a minor IL-17
expressing population (4%). A similar distribution was
found in head and neck, ovarian, endometrial, prostate,
breast, lung and colon carcinoma. A high number of IL-17
expressing cells was an independent prognostic factor for
poor survival in early stage disease (p = 0.016, n = 160). A
high number of Th17 cells was an independent prognostic
factor for improved disease-specific survival (p = 0.026),
suggesting Th17 cells are part of an anti-tumor immune
response. IL6 independently predicted poor survival in cer-
vical cancer. IL17 expressed by Th17 cells could counteract
the tumor promoting effects of IL6, even more so combined
with a Th2 response characterized by IL5. Since RNA
levels, in contrast to protein levels, are extremely low in
activated neutrophils, the IL17 RNA levels measured most
likely represented Th17 cells. Th17 cells, despite being a
minor IL-17 expressing subpopulation, were also associated
with improved survival in squamous cervical cancer. Total
IL-17 expressing cells, primarily representing neutrophils,
rather associated with poor survival in early stage disease.
Measuring IL6, especially in combination with IL17 and
IL5 expression, may improve the accuracy of predicting
prognosis and support the development of anti-IL-6 com-
bined with anti-VEGF-A therapy in cervical cancer.
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